Latest News

Arzerra Plus Chlorambucil Gets FDA Nod

Arzerra Plus Chlorambucil Gets FDA Nod

The FDA has approved a new indication for Arzerra to use in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia.

Volasertib Designated Orphan Drug for AML

Volasertib Designated Orphan Drug for AML

The FDA has granted Orphan Drug designation to volasertib (Boehringer Ingelheim) for acute myeloid leukemia (AML).

AbbVie Initiates Veliparib Trial for NSCLC

AbbVie Initiates Veliparib Trial for NSCLC

AbbVie announced the initiation of a Phase 3 trial evaluating the safety and efficacy of veliparib in patients with previously untreated locally advanced or metastatic squamous non-small cell lung cancer.

Six Percent of CRCs Are Interval Tumors

Six Percent of CRCs Are Interval Tumors

Six percent of patients with colorectal cancer (CRC) have interval cancers, which develop within six to 60 months of colonoscopy.

Chemo Ups Survival in Bladder Cancer

Chemo Ups Survival in Bladder Cancer

The use of neoadjuvant and adjuvant chemotherapy for the treatment of muscle-invasive bladder cancer is associated with a survival benefit in the general population, and may be underutilized.

More News

New Health Secretary to Face Health Care Reform Hurdles

With the resignation of U.S. Health and Human Services Secretary Kathleen Sebelius on Friday, the Affordable Care Act will get a fresh face.

Fewer Americans Overwhelmed by Medical Bills

While millions of Americans still feel hamstrung by medical expenses, a new government report shows that some people are getting relief.

Sebelius Resigns as HHS Secretary

US Health and Human Services Secretary Kathleen Sebelius is stepping down from her position, after overseeing the troubled rollout of the Affordable Care Act.

Medicare Paid Some Docs $3 Million Each in 2012

A small number of doctors received at least $3 million each in Medicare payments in 2012, for a total of nearly $1.5 billion.

Choosing Wisely Selections Largely Based on Costs

Most services included in specialty medical societies' Top 5 lists for the Choosing Wisely campaign are based on evidence demonstrating equivalent but not superior benefit.

Majority of Women Lack Accurate Knowledge of Their Own Breast Cancer Risk

Caucasian women overestimate their risk of breast cancer while African American and Hispanic women underestimate their risk, according to research presented at BCS 2013.

Survey Identifies Modifiable Barriers to Mammography Screening Among Rural US Women

A survey presented at BCS 2013 has found a number of factors that cause rural US women to avoid breast cancer screening.

Perioperative MRI of Uncertain Benefit for Women with DCIS

The benefit of perioperative MRI for women with ductal carcinoma in situ (DCIS) is "uncertain," found a study presented during BCS 2013.

Dr. Edith Perez's Recommended Abstracts at BCS 2013 Editorial Board member Dr. Edith Perez of the Mayo Clinic, Jacksonville, FL, recommends high impact abstracts at the Breast Cancer Symposium 2013.

Radiotherapy for DCIS Is Not Associated With Increased Cardiovascular Disease

Women who underwent radiation for ductal carcinoma in situ do not face an increased risk of cardiovascular disease, found a study presented at BCS 2013.

Prostate Brachytherapy On the Decline

Use of this treatment for localized prostate cancer has been decreasing since 2002, perhaps due to increasing use of radical prostatectomy.

Adding ADT to Radiotherapy Improves Prostate Cancer Outcomes

The combined treatment was associated with a reduced risk of biochemical and clinical progression compared with radiotherapy alone.

Osteoporosis May Be Present Before Prostate Cancer ADT

Danish study reveals a 10% prevalence of osteoporosis among men due to start androgen-deprivation therapy.

Renal Mass Biopsy Seldom Used Pre-RCC Surgery

Only 17% and 20% of patients undergoing radical or partial nephrectomy, respectively, had a renal mass biopsy in advance of surgery.

PSA Nadir in ADT Recipients: The Lower, The Better

The nadir should be below 0.01 ng/mL because even levels of 0.01 to 0.2 ng/mL predict an increased risk of adverse outcomes.

Sign Up for Free e-newsletters

Enter Our April Contest

Start the contest today

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs